Fig. 6

Impact of ASCs, metformin, or combination late-stage therapy on functional outcomes linked to RISF. A Skin architecture at day 42 post 40Gy irradiation. Local injection of 3 million autologous ASCs (C57BL/6 origin ASCs injected in irradiated C57BL/6 host) on day 14 post-irradiation or 100mg/kg body weight metformin was injected 3 times a week starting day 14, or a combination of both ASCs and metformin or saline (control) was injected. B The degree of leg motion was measured on day 42 (B) post-irradiation and plotted (n = 8–10 per group). C Skin architecture at day 42 post 40Gy irradiation. Local injection of 3 million allogeneic ASCs (FVB origin ASCs injected in irradiated C57BL/6 host) on day 14 post-irradiation or 100mg/kg body weight metformin was injected 3 times a week starting day 14, or a combination of both ASCs and metformin or saline (control) was injected. D The degree of leg motion was measured on day 42 (D) post-irradiation and plotted (n = 8–10 per group). E comparison of prophylactic and late-stage therapy on the outcomes of mitigation. P value < 0.05 = ^*, < 0.005 = ^**, < 0.0005 = ^***